to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Ratain, Mark J.
One or more keywords matched the following items that are connected to
Ratain, Mark J.
Randomized Controlled Trials as Topic
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
EGFR pharmacogenomics: the story continues to mutate and evolve.
Hairy cell leukemia. Current management.
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Optimising the design of phase II oncology trials: the importance of randomisation.
Bar the windows but open the door to randomization.
Resampling phase III data to assess phase II trial designs and endpoints.
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Randomized phase II trials: a long-term investment with promising returns.
Individualizing dosing of irinotecan.
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?
Meaningful use of pharmacogenetics.
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Trials Randomized Clinical